CO6150148A2 - Un inhibidor aminoisoquinolina trombina con biodisponibilidad mejorada - Google Patents

Un inhibidor aminoisoquinolina trombina con biodisponibilidad mejorada

Info

Publication number
CO6150148A2
CO6150148A2 CO09023453A CO09023453A CO6150148A2 CO 6150148 A2 CO6150148 A2 CO 6150148A2 CO 09023453 A CO09023453 A CO 09023453A CO 09023453 A CO09023453 A CO 09023453A CO 6150148 A2 CO6150148 A2 CO 6150148A2
Authority
CO
Colombia
Prior art keywords
compound
thrombine
aminoisoquinoline
inhibitor
pharmaceutically acceptable
Prior art date
Application number
CO09023453A
Other languages
English (en)
Inventor
Robert Gilfillan
David Jonathan Bennett
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of CO6150148A2 publication Critical patent/CO6150148A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1.- El compuesto N-(2-oxo-2-propoxietil)-β-feniI-D-fenilalaniI-N-[(1-amino-6- isoquinolinil)metil]-L-prolinamida o su sal farmacéuticamente aceptable.2.- El compuesto de la reivindicación 1 como la sal diclorhidrato.3.- Una composición farmacéutica que comprende el compuesto de la reivindicación 1 y sus auxiliares farmacéuticamente aceptables.4.- El compuesto de la reivindicación 1 para uso en terapia.5.- Uso del compuesto de la reivindicación 1 para la fabricación de un medicamento para tratar o para prevenir enfermedades mediadas por trombina.6.- El compuesto N-(carboximetil)-β-fenil-D-fenilalanil-N-[(1-amino-6-isoquinolinil)metil]-L-proIinamida o su sal farmacéuticamente aceptable.
CO09023453A 2006-08-08 2009-03-06 Un inhibidor aminoisoquinolina trombina con biodisponibilidad mejorada CO6150148A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06118608 2006-08-08

Publications (1)

Publication Number Publication Date
CO6150148A2 true CO6150148A2 (es) 2010-04-20

Family

ID=37561257

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09023453A CO6150148A2 (es) 2006-08-08 2009-03-06 Un inhibidor aminoisoquinolina trombina con biodisponibilidad mejorada

Country Status (21)

Country Link
US (1) US8299091B2 (es)
EP (1) EP2054402B1 (es)
JP (1) JP5271904B2 (es)
KR (1) KR20090048496A (es)
CN (1) CN101511816B (es)
AR (1) AR062215A1 (es)
AU (1) AU2007283596B2 (es)
BR (1) BRPI0715384A2 (es)
CA (1) CA2659154A1 (es)
CL (1) CL2007002294A1 (es)
CO (1) CO6150148A2 (es)
IL (1) IL196783A (es)
MX (1) MX2009001384A (es)
MY (1) MY143949A (es)
NO (1) NO20090448L (es)
NZ (1) NZ574550A (es)
PE (1) PE20080526A1 (es)
RU (1) RU2437879C2 (es)
TW (1) TWI389899B (es)
WO (1) WO2008017650A1 (es)
ZA (1) ZA200900903B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150047597A (ko) * 2012-08-27 2015-05-04 어레이 바이오파마 인크. 과증식성 질환의 치료를 위한 세린/트레오닌 키나아제 억제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
GB9322976D0 (en) * 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
US5523308A (en) * 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
NZ336046A (en) * 1996-12-06 2000-10-27 Cortech Inc Serine protease inhibitors containing substituted oxadiazole, thiadiazole and triazole peptide derivatives
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
TW575567B (en) 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
EP1303491A1 (en) * 2000-07-12 2003-04-23 Akzo Nobel N.V. Thrombin inhibitors comprising an aminoisoquinoline group

Also Published As

Publication number Publication date
CA2659154A1 (en) 2008-02-14
JP5271904B2 (ja) 2013-08-21
BRPI0715384A2 (pt) 2013-06-18
WO2008017650A1 (en) 2008-02-14
RU2009107917A (ru) 2010-09-20
AU2007283596A1 (en) 2008-02-14
IL196783A (en) 2013-03-24
AR062215A1 (es) 2008-10-22
CL2007002294A1 (es) 2008-04-18
CN101511816B (zh) 2013-01-02
ZA200900903B (en) 2010-06-30
TWI389899B (zh) 2013-03-21
NO20090448L (no) 2009-02-05
KR20090048496A (ko) 2009-05-13
EP2054402A1 (en) 2009-05-06
US20100305153A1 (en) 2010-12-02
JP2010500321A (ja) 2010-01-07
PE20080526A1 (es) 2008-06-13
MX2009001384A (es) 2009-04-30
AU2007283596B2 (en) 2012-07-05
TW200821294A (en) 2008-05-16
NZ574550A (en) 2010-09-30
RU2437879C2 (ru) 2011-12-27
EP2054402B1 (en) 2013-11-27
MY143949A (en) 2011-07-29
US8299091B2 (en) 2012-10-30
CN101511816A (zh) 2009-08-19
IL196783A0 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
GT201100181A (es) "inhibidores de proteina cinasa"
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
AR075204A1 (es) Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
CO6501168A2 (es) Inhibidor de la map cinasa p38
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CO6160236A2 (es) Inhibidor de quinasa
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
AR061238A1 (es) Compuestos de oxilmilo macrociclico inhibidores de proteasa de hepatitis c
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
MX2009013332A (es) Inhibidores de ire-1 alfa.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
AR074471A1 (es) Compuesto 5(5-(2-(3-aminopropoxi) - 6 - metoxifenil) -1h- pirazol-3- ilamino ) pirazin -2-carbonitrilo , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para inhibir chk1 y para tratar cancer
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
BR112023020442A2 (pt) Inibidor da protease 1 específica de ubiquitina (usp1)
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.